Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Oral Presentations: Clinical Diabetes/Therapeutics

16-OR: Contributions of Chronic Kidney Disease and Cardiovascular Disease to Medical Costs of Type 2 Diabetes

  1. GREGORY A. NICHOLS,
  2. ANASTASIA V. USTYUGOVA,
  3. ANOUK DERUAZ-LUYET and
  4. KIMBERLY G. BRODOVICZ
  1. Portland, OR, Ingelheim, Germany, Ridgefield, CT
Diabetes 2019 Jun; 68(Supplement 1): -. https://doi.org/10.2337/db19-16-OR
Previous
  • Article
  • Figures & Tables
  • Info & Metrics
Loading

Abstract

Medical costs of type 2 diabetes (T2D) are driven by the presence of microvascular and macrovascular complications. We compared annual costs of T2D patients with and without chronic kidney disease (CKD) and cardiovascular disease (CVD). We used the electronic medical records of Kaiser Permanente Northwest to identify 37,684 patients with T2D with an eGFR in 2016 or 2017. We grouped them according to presence of CKD (2 eGFR <60mL/min/1.73m2), CVD (ischemic heart disease, stroke or heart failure), or both. We used 1 year of follow-up data to compare the annual outpatient, inpatient, emergency, pharmaceutical, and total medical care costs (2017 USD) between the four groups adjusted for age, sex, and non-white race. Of the 37,684 total patients, 16% had CKD without CVD, 12% (n=4,596) had CVD without CKD, 11% (n=4,089) had both, and 61% had neither. Patients with neither CKD nor CVD incurred adjusted total costs of $7,582 (Table). Costs were significantly higher in total and for all components among patients with CKD without CVD, and higher still among those with CVD without CKD. When both CKD and CVD were present, total, inpatient and emergency costs were approximately the sum of costs which each condition existed alone, CKD and CVD each approximately double annual medical costs, but the combination of the two conditions increases costs nearly 4-fold, underscoring the need for preventive therapies.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Disclosure G.A. Nichols: Research Support; Self; Amarin Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Scientific Affairs, LLC., Merck Sharp & Dohme Corp. A.V. Ustyugova: Employee; Self; Boehringer Ingelheim International GmbH. A. Deruaz-Luyet: Employee; Self; Boehringer Ingelheim International GmbH. Employee; Spouse/Partner; Medtronic, Sanofi. K.G. Brodovicz: Employee; Self; Boehringer Ingelheim Pharmaceuticals, Inc.

Funding Boehringer Ingelheim

  • © 2019 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

Previous
Back to top
Diabetes: 68 (Supplement 1)

In this Issue

June 2019, 68(Supplement 1)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
16-OR: Contributions of Chronic Kidney Disease and Cardiovascular Disease to Medical Costs of Type 2 Diabetes
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
16-OR: Contributions of Chronic Kidney Disease and Cardiovascular Disease to Medical Costs of Type 2 Diabetes
GREGORY A. NICHOLS, ANASTASIA V. USTYUGOVA, ANOUK DERUAZ-LUYET, KIMBERLY G. BRODOVICZ
Diabetes Jun 2019, 68 (Supplement 1) 16-OR; DOI: 10.2337/db19-16-OR

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

16-OR: Contributions of Chronic Kidney Disease and Cardiovascular Disease to Medical Costs of Type 2 Diabetes
GREGORY A. NICHOLS, ANASTASIA V. USTYUGOVA, ANOUK DERUAZ-LUYET, KIMBERLY G. BRODOVICZ
Diabetes Jun 2019, 68 (Supplement 1) 16-OR; DOI: 10.2337/db19-16-OR
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Tables
  • Info & Metrics

Related Articles

Cited By...

More in this TOC Section

Oral Presentations: Clinical Diabetes/Therapeutics

  • 231-OR: Phase I Study Investigating the PD, PK, and Safety of AT247 in Comparison with Novorapid and Fiasp
  • 357-OR: Efficacy and Safety of Dulaglutide 3mg and 4.5mg vs. Dulaglutide 1.5mg: 52-Week Results from AWARD-11
  • 355-OR: Effects of a Six-Week Intervention with Glucagon-Like Peptide-1 Analogue on Pancreatic Volume, Edema, and DNA Synthesis in Obese Men
Show more Oral Presentations: Clinical Diabetes/Therapeutics

OR: Health Care Delivery—Economics/Quality Improvement

  • 14-OR: The Cost of Chronic Kidney Disease Progression in Type 2 Diabetes Patients
  • 15-OR: Renal Outcomes from the DECLARE-TIMI 58 Trial: Quantifying the Health-Care Implications
  • 345-OR: A Retrospective U.S. Real-World Evidence Study on Glycemic Goal Achievement within 2 Years Post-Basal Insulin Initiation
Show more OR: Health Care Delivery—Economics/Quality Improvement

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.